Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy

• Main Authors: Xia L, Qian W, Yang M, Li Q, Liu F, Xie Y
• Format: Article
• Language: English
• Published: Dove Medical Press 2015-09-01
• Series: OncoTargets and Therapy
• Online Access: https://www.dovepress.com/comparison-of-the-utility-and-applicability-of-the-sokal-hasford-and-e-peer-reviewed-article-OTT

Leiming Xia,1,2,* Wei Qian,3,* Mingzhen Yang,3,4 Qingsheng Li,4 Fei Liu,5 Yanyan Xie4 1Department of Hematology, The Third Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 2Department of Hematology, Hefei Binhu Hospital, Hefei, People’s Republic of China; 3Department of Hematology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 4Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 5Department of Hematology, The Second People’s Hospital of Wuhu, Wuhu, People′s Republic of China *These authors contributed equally to this work Background: Tyrosine kinase inhibitors are increasingly used to treat chronic myeloid leukemia (CML), but loss of complete cytogenetic response (CCyR) indicates treatment failure.Aim: To compare the efficacy of Sokal, European Treatment Outcome Study (EUTOS), and Hasford prognostic scores with 3-month and 12-month CCyR, event-free survival (EFS) and progression-free survival (PFS) in patients with chronic-phase CML (CP-CML) undergoing imatinib therapy.Methods: We retrospectively analyzed the outcome of 210 patients with CP-CML treated at the First Affiliated Hospital of Anhui Medical University treated between January 2006 and December 2013. Sokal, EUTOS, and Hasford scores were compared with 3-month and 12-month CCyR, EFS, and PFS.Results: Kaplan–Meier analyses revealed that 3-month and 12-month CCyR and PFS were lower in patients with high EUTOS scores, and intermediate or high Sokal and Hasford scores (all P<0.05). Furthermore, EFS was lower in patients with intermediate or high Sokal and Hasford scores (both P<0.05). Hasford score (hazard ratio =2.608, 95% confidence interval: 1.473–4.617, P=0.001) was independently associated with 3-month CCyR.Conclusion: Although all three scoring systems were associated with EFS, PFS, and 3-month and 12-month CCyR in the Kaplan–Meier analyses (except EFS with EUTOS), only the Hasford score was independently associated with 3m-CCyR, while EUTOS score and Sokal score were not independently associated with any of these outcomes. Keywords: chronic-phase chronic myeloid leukemia, prognosis, Sokal, EUTOS, Hasford, complete cytogenic response